Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial
暂无分享,去创建一个
Robert P. Giugliano | Francesco Nordio | Anthony Dalby | Elliott M. Antman | E. Antman | R. Giugliano | E. Braunwald | M. Mercuri | F. Nordio | S. Wiviott | M. Dorobanțu | A. Eisen | R. Corbalán | Stephen D. Wiviott | Eugene Braunwald | Michele Mercuri | Christian T. Ruff | Alon Eisen | Ramón Corbalán | Maria Dorobantu | Hans Lanz | Howard Rutman | C. Ruff | H. Lanz | A. Dalby | H. Rutman
[1] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[2] M. Rich,et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.
[3] H. Crijns,et al. Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. , 2006, The American journal of cardiology.
[4] K. Reinier,et al. Epidemiology of sudden cardiac death: clinical and research implications. , 2008, Progress in cardiovascular diseases.
[5] S. Chugh. Early identification of risk factors for sudden cardiac death , 2010, Nature Reviews Cardiology.
[6] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[7] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[8] C. Albert,et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. , 2011, JAMA.
[9] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[10] C. Albert,et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. , 2011, JAMA.
[11] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[12] N. Deshpande. Apixaban versus warfarin in patients with atrial fibrillation , 2012 .
[13] J. Le Heuzey,et al. Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study , 2013, Circulation.
[14] Elsayed Z Soliman,et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. , 2013, JAMA internal medicine.
[15] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[16] K. Reinier,et al. An intersection of atrial fibrillation with sudden death: look both ways, and proceed with caution. , 2013, JAMA internal medicine.
[17] Richard B Devereux,et al. Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy , 2013, Circulation. Arrhythmia and electrophysiology.
[18] Jennifer G. Robinson,et al. ACCF/AHA TASK FORCE MEMBERS , 2013 .
[19] H. Tan,et al. Atrial Fibrillation Is an Independent Risk Factor for Ventricular Fibrillation: A Large-Scale Population-Based Case-Control Study , 2014, Circulation. Arrhythmia and electrophysiology.
[20] C. Murray,et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.
[21] M. Turakhia,et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. , 2014, Journal of the American College of Cardiology.
[22] Kumar Narayanan,et al. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. , 2014, JACC. Heart failure.
[23] L. Chen,et al. Atrial fibrillation and its association with sudden cardiac death. , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[24] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[25] A. Kadish,et al. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. , 2014, Journal of the American College of Cardiology.
[26] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[27] Wataru Shimizu,et al. The spectrum of epidemiology underlying sudden cardiac death. , 2015, Circulation research.
[28] G. Fonarow,et al. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. , 2015, Journal of the American College of Cardiology.
[29] Jason P. Fine,et al. Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .
[30] ReviewTM. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes , 2022 .